Retatrutide, a new dual agonist of the GLP-1 target and glucose-dependent secreted polypeptide (GIP) target, is demonstrating promising outcomes in early human studies. Recent copyrightination indicates https://shopretatrutidepeptide.com/retatrutide-research-knowledge-hub/